Tag: TMB

BMS files Opdivo/Yervoy combo for lung cancer

by Selina McKee | Jun 22, 2018 | News | 0

US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain patients.

Opdivo/Yervoy combo beats chemo on PFS in lung cancer

by Selina McKee | Feb 6, 2018 | News | 0

Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).